Page 292

House Bill No. 5506

Public Act No. 22-118 292 of 739

(1) the number of vacant positions in each agency; (2) the number of persons hired in each agency during the previous month; and (3) the number of persons who refused an offer of hire by each agency in the previous month. Sec. 200. (NEW) (Effective July 1, 2022) (a) As used in this section and section 201 of this act: (1) "MDMA" means the synthetic psychoactive drug, 3,4- methylenedioxymethamphetamine, commonly known as ecstasy or molly, that acts as a serotonin receptor agonist and reuptake inhibitor of serotonin and dopamine. (2) "Psilocybin" means a serotonin receptor agonist that occurs naturally in some mushroom species. (3) "Qualified patient" means a resident of the state who is (A) a veteran, (B) a retired first responder, or (C) a direct care health care worker. (4) "Qualified applicant" means a provider of mental or behavioral health services that has received approval from the federal Food and Drug Administration as an approved treatment site with an expanded access protocol that allows the provider access to an investigational drug for treatment use, including emergency use, pursuant to 21 CFR 312, as amended from time to time. (5) "Approved treatment site" means the location where a qualified applicant that has been selected under subsection (e) of this section as a provider of MDMA-assisted or psilocybin-assisted therapy under the pilot program established pursuant to subsection (b) of this section will provide such therapy. (b) There is established, within available appropriations, at the Connecticut Mental Health Center, established pursuant to section 17a-